Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if ponatinib can help to control Chronic
Myeloid Leukemia (CML) in accelerated phase. The safety of this drug will also be studied.
Ponatinib is designed to block the function of BCR-ABL, which is the abnormal protein
responsible for causing leukemia in certain cells.
Ponatinib may cause a blood clot to form in an artery or in a vein. Depending on the location
of the clot, this could cause a heart attack, a stroke, severe damage to other tissue, or
death. A blood clot may occur within 2 weeks after you start taking the drug. About 25% (1 in
4) of patients taking the drug form an abnormal clot. Blood clots can occur in patients that
do not have other known risk factors for forming clots. If you develop a blood clot, you will
need to stop taking ponatinib. In some cases, emergency surgery could be needed to remove the
clot and restore blood flow.